{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T18:37:13Z","timestamp":1778265433174,"version":"3.51.4"},"reference-count":19,"publisher":"Japan Endocrine Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1507\/endocrj.ej20-0216","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T22:06:31Z","timestamp":1598652391000},"page":"17-29","source":"Crossref","is-referenced-by-count":9,"title":["Open-label, multicenter, dose-titration study to determine the efficacy and safety of tolvaptan in Japanese patients with hyponatremia secondary to syndrome of inappropriate secretion of antidiuretic hormone"],"prefix":"10.1507","volume":"68","author":[{"given":"Hiroshi","family":"Arima","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohisa","family":"Motozawa","sequence":"additional","affiliation":[{"name":"Clinical Development Headquarters, Otsuka Pharmaceutical Co., Ltd, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Mouri","sequence":"additional","affiliation":[{"name":"Clinical Development Headquarters, Otsuka Pharmaceutical Co., Ltd, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Clinical Development Headquarters, Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Hirano","sequence":"additional","affiliation":[{"name":"Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"San-e","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, International University of Health and Welfare Hospital, Tochigi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Cuesta M, Garrahy A, Thompson CJ (2016) SIAD: practical recommendations for diagnosis and management. J Endocrinol Invest 39: 991\u20131001.","DOI":"10.1007\/s40618-016-0463-3"},{"key":"2","unstructured":"2 Peri A, Giuliani C (2014) Management of euvolemic hyponatremia attributed to SIADH in the hospital setting. Minerva Endocrinol 39: 33\u201341."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH (2007) Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 120: S1\u2013S21.","DOI":"10.1016\/j.amjmed.2007.09.001"},{"key":"4","unstructured":"4 Ishikawa S (2011) SIADH. In: Orita Y (ed) Vasopressin and its receptor antagonism basic principles and clinical applications. Osaka: Medical Review, 141\u2013149 (In Japanese)."},{"key":"5","unstructured":"5 Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, et al. (2014) Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol 170: G1\u2013G47."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Verbalis JG, Greenberg A, Burst V, Haymann JP, Johannsson G, et al. (2016) Diagnosing and treating the syndrome of inappropriate antidiuretic hormone secretion. Am J Med 129: 537.e9\u2013537.e23.","DOI":"10.1016\/j.amjmed.2015.11.005"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, et al. (2006) Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355: 2099\u20132112.","DOI":"10.1056\/NEJMoa065181"},{"key":"8","unstructured":"8 Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, et al. (1998) OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 287: 860\u2013867."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Humayun MA, Cranston IC (2017) In-patient tolvaptan use in SIADH: care audit, therapy observation and outcome analysis. BMC Endocr Disord 17: 69.","DOI":"10.1186\/s12902-017-0214-2"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Chen S, Zhao JJ, Tong NW, Guo XH, Qiu MC, et al. (2014) Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH. J Clin Pharmacol 54: 1362\u20131367.","DOI":"10.1002\/jcph.342"},{"key":"11","unstructured":"11 Han SW, Yi JH, Kang KP, Kim HY, Kim SW, et al. (2018) Safety and efficacy of tolvaptan in Korean patients with hyponatremia caused by the syndrome of inappropriate antidiuretic hormone. J Korean Med Sci 33: e112."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Verbalis JG, Adler S, Schrier RW, Berl T, Zhao Q, et al. (2011) Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol 164: 725\u2013732.","DOI":"10.1530\/EJE-10-1078"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Castello LM, Baldrighi M, Panizza A, Bartoli E, Avanzi GC (2017) Efficacy and safety of two different tolvaptan doses in the treatment of hyponatremia in the emergency department. Intern Emerg Med 12: 993\u20131001.","DOI":"10.1007\/s11739-016-1508-5"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Harbeck B, Lindner U, Haas CS (2016) Low-dose tolvaptan for the treatment of hyponatremia in the syndrome of inappropriate ADH secretion (SIADH). Endocrine 53: 872\u2013873.","DOI":"10.1007\/s12020-016-0912-y"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Morris JH, Bohm NM, Nemecek BD, Crawford R, Kelley D, et al. (2018) Rapidity of correction of hyponatremia due to syndrome of inappropriate secretion of antidiuretic hormone following tolvaptan. Am J Kidney Dis 71: 772\u2013782.","DOI":"10.1053\/j.ajkd.2017.12.002"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Tzoulis P, Waung JA, Bagkeris E, Carr H, Khoo B, et al. (2016) Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion. Clin Endocrinol (Oxf) 84: 620\u2013626.","DOI":"10.1111\/cen.12943"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Sterns RH (2018) Tolvaptan for the syndrome of inappropriate secretion of antidiuretic hormone: is the dose too high? Am J Kidney Dis 71: 763\u2013765.","DOI":"10.1053\/j.ajkd.2018.02.355"},{"key":"18","doi-asserted-by":"crossref","unstructured":"19 Seay NW, Lehrich RW, Greenberg A (2020) Diagnosis and management of disorders of body tonicity\u2014hyponatremia and hypernatremia: core curriculum 2020. Am J Kidney Dis 75: 272\u2013286.","DOI":"10.1053\/j.ajkd.2019.07.014"},{"key":"19","doi-asserted-by":"crossref","unstructured":"20 Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, et al. (2010) Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 21: 705\u2013712.","DOI":"10.1681\/ASN.2009080857"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/68\/1\/68_EJ20-0216\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T03:25:13Z","timestamp":1611977113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/68\/1\/68_EJ20-0216\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej20-0216","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}